Belgium· BE-AMP-SAM424261-00

Antediar 125 mg

A saccharomyces boulardii product containing saccharomyces boulardii, registered in Belgium by Will Pharma. The same ATC class is registered in 10 of our 19 countries.

ATC A07FA02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAntediar 125 mgATCA07FA02REGISTER NO.BE-AMP-SAM424261-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Saccharomyces boulardii is registered in 10 of 19 countries.

Countries holding a registration under ATC A07FA02 (saccharomyces boulardii), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Saccharomyces boulardii · ATC A07FA02

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of saccharomyces boulardii costs, country by country.

Normalised to the WHO defined daily dose (1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Saccharomyces boulardii · price per daily dose (1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$4.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Saccharomyces boulardii
Manufacturer
Will Pharma
Country
Belgium (BE)
ATC code
A07FA02
ATC class
Saccharomyces boulardii
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Saccharomyces boulardii in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All saccharomyces boulardii products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

  • Austria · Yomogi
  • Cyprus · Bioflor
  • Germany · Boulardii Pz Entsprechend Mindestens 10^10 Lebensfähige Zellen/G, Lyophilisiert, Ceritract
  • Italy · Codex, Preparazione H
  • Portugal · Prolif
  • Sweden · Precosa
  • Slovakia · Yomogi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/adcd08cd-8329-4f92-87de-74074a8bff63
GET /v1/drugs/adcd08cd-8329-4f92-87de-74074a8bff63?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Antediar 125 mg",
  "name_fr": "Antediar 125 mg",
  "name_nl": "Antediar 125 mg",
  "amp_code": "SAM424261-00",
  "strengths": [
    "125.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Saccharomyces boulardii"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Saccharomyces Boulardii",
  "authorisation_numbers": [
    "BE424261"
  ]
}

See everything about saccharomyces boulardii.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.